GeneSort

Company Overview

Snapshot

Founded in September 2013 by Dr. Ayala Stadler-Lagziel, GeneSort operates with 1–10 employees. The company raised $2.2M across one funding round from Singulariteam. In May 2017, GeneSort was acquired by AID Partners.

Business overview

GeneSort is a molecular diagnostics company that integrates molecular genomics with personalized therapeutic approaches. The company's core technology focuses on using patients' genetic DNA profiles to assist physicians in selecting safe, effective, and tailored treatments. GeneSort provides diagnostic services primarily in the areas of cancer and hereditary diseases, serving markets within the Health Tech & Life Sciences sector.

Strategic signal

In May 2017, GeneSort was acquired by AID Partners for $23 million, as reported by Globes. This acquisition signals a strategic validation of GeneSort's molecular diagnostics technology and its potential in the personalized medicine market, indicating a successful exit for early investors and a consolidation within the health tech and life sciences sector.

Company Intelligence Q&A

When was GeneSort founded?

GeneSort was founded in September 2013.

Who founded GeneSort?

GeneSort was co-founded by Dr. Ayala Stadler-Lagziel.

What is GeneSort's primary focus?

GeneSort focuses on integrating molecular genomics with personalized therapeutic approaches, providing diagnostic services in cancer and hereditary diseases.

When was GeneSort acquired and by whom?

GeneSort was acquired by AID Partners in May 2017.

What was the reported acquisition amount for GeneSort?

In May 2017, AID Partners acquired GeneSort for $23 million, as reported by Globes.